Revaclear Dialyzer

Revaclear Dialyzer

Advantages of the Revaclear Dialyzer

#1

The Poracton membrane (PAES/PVP, BPA-Free) provides effective permeability with minimal resistance to diffusion.1-3

#2

Removes small and conventional middle molecules during hemodialysis therapy at a rate equivalent to that of a dialyzer with a 22% larger surface area.4

#3

May help manage patient risks by reducing exposure of blood, potentially reducing clotting and inflammation.5

#4

Optimizing performance4 with safety and biocompatibility in mind.

Optimizing high-flux performance

The Revaclear Dialyzer series is a range of high-efficiency, high-flux dialyzers designed to enhance safety and biocompatibility for patients, as well as optimize clearance with a smaller surface area.6 With the Poracton membrane design, the Revaclear series provides effective permeability with minimal resistance to diffusion.1-3

Revaclear Dialyzer

Learn more about the Revaclear Dialyzer series

Read more about how the Revaclear series enhances the safety and biocompatibility of high-flux treatments for patients.

Download brochure Download datasheet

Related products

Important Safety Information

Intended Use/Purpose: Revaclear hemodialyzers/diafilters (“device” throughout the text) are intended to purify blood in hemodialysis and hemodiafiltration.

Indication: Revaclear devices are indicated for the treatment of chronic or acute renal failure.

For safe and proper use of the device, please refer to the Instructions for Use.

Vantive, AK 98, Polyflux, Poracton, Revaclear and Theranova are trademarks of Vantive Health LLC or its affiliates.

References

  1. Ronco C, Crepaldi C, Brendolan A, et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol Dial Transplant. 2003;18(Suppl 7):vii10-20.

  2. Ward R, Ouseph R. Modification of membrane characteristics allows a reduction in dialyzer membrane area without loss of performance. Abstract SA-PO510, presented at the 40th American Society of Nephrology (ASN) Congress. San Francisco, USA, 2007.

  3. Bhimani JP, Ouseph R, Ward RA. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant. 2010;25:3990-3995.

  4. Mauric A, et al. Poster SP401, presented at 50th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. Istanbul (Turkey), 2013.

  5. Vantive Health LLC. Revaclear dialyzers: Optimized for efficient high-flux HD treatments, May 2013.

  6. Vantive Health LLC. Revaclear White Paper. USMP/MG3/140052, May 2013.